Nephrocare Health Services has disclosed that its officials will participate in an investor conference scheduled for June 2, 2026. The intimation was made pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations.

The meeting is organized by Axis Capital and is set to take place in Mumbai. It will serve as a platform for group interactions as well as one-on-one meetings with analysts and institutional investors. The event is scheduled to commence at 11:00 A.M. IST onwards.

The company clarified that the discussions during the conference will be strictly based on publicly available information. Nephrocare Health Services confirmed that no unpublished price sensitive information (UPSI) is intended to be discussed during these interactions. The schedule remains subject to changes due to exigencies on the part of the host or the company.

Nephrocare Health Services Limited has reported its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board, in its meeting held on May 19, 2026, approved the results along with several strategic decisions regarding its overseas subsidiaries.

For the financial year ended March 31, 2026, the company reported a net loss of ₹80.60 million, a significant shift from the net profit of ₹342.36 million recorded in the previous year. Revenue from operations for the year increased to ₹6,297.43 million from ₹5,435.97 million in the prior year. In the quarter ended March 31, 2026, the company returned to profitability with a net profit of ₹108.88 million, compared to a net profit of ₹56.72 million in the corresponding quarter of the previous year.

The board approved a further investment of up to ₹10 crore in Nephrocare Health Services Nepal Private Limited, its wholly owned subsidiary. This investment will be made in one or more tranches towards meeting business operations, working capital requirements, and general corporate purposes. Additionally, the board granted in-principal approval for providing collateral or security support aggregating up to ₹70 crore each to two overseas subsidiaries: Nephrocare Health Services International Pte. Ltd. in Singapore and Nephrocare Health Services Saudi Arabia Company. These guarantees are intended to enable the subsidiaries to avail credit facilities from overseas banks.

The company also re-appointed M/s. BDO India LLP as the Internal Auditor for the financial year 2026-27 based on the recommendations of the Audit Committee. The statutory auditors, M/s. B S R and Co, issued an audit report with an unmodified opinion on the standalone and consolidated financial results.

Standalone Financial Results

The standalone financial performance for the year reflects the impact of non-cash and non-recurring items. The company incurred an interest expense of ₹371.89 million on financial liabilities measured at fair value through profit or loss during the year. Total expenses for the year rose to ₹6,489.46 million from ₹5,138.68 million in the previous year.

Consolidated Financial Results

On a consolidated basis, the group reported a net profit of ₹768.40 million for the year ended March 31, 2026, up from ₹670.96 million in the previous year. Revenue from operations for the group stood at ₹9,988.45 million for the year. The profit for the quarter ended March 31, 2026, was ₹303.70 million.